Role of Interleukin-1 Family Members and Signaling Pathways in KSHV Pathogenesis.
Kaposi’s sarcoma
Kaposi’s sarcoma-associated herpesvirus
interleukin-1
multicentric Castleman’s disease
primary effusion lymphoma
Journal
Frontiers in cellular and infection microbiology
ISSN: 2235-2988
Titre abrégé: Front Cell Infect Microbiol
Pays: Switzerland
ID NLM: 101585359
Informations de publication
Date de publication:
2020
2020
Historique:
received:
27
07
2020
accepted:
13
10
2020
entrez:
16
11
2020
pubmed:
17
11
2020
medline:
22
6
2021
Statut:
epublish
Résumé
Kaposi's sarcoma-associated herpesvirus (KSHV) represents the etiological agent for several human malignancies, including Kaposi's sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castleman's disease (MCD), which are mostly seen in immunocompromised patients. In fact, KSHV has developed many strategies to hijack host immune response, including the regulation of inflammatory cytokine production. Interleukin-1 (IL-1) family represents a major mediator for inflammation and plays an important role in both innate and adaptive immunity. Furthermore, a broadening list of diseases has revealed the pathologic role of IL-1 mediated inflammation. In the current mini-review, we have summarized recent findings about how this oncogenic virus is able to manipulate the activities of IL-1 signaling pathway to facilitate disease progression. We also discuss the therapeutic potential of IL-1 blockade against KSHV-related diseases and several unsolved questions in this interesting field.
Identifiants
pubmed: 33194830
doi: 10.3389/fcimb.2020.587929
pmc: PMC7662392
doi:
Substances chimiques
Interleukin-1
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
587929Informations de copyright
Copyright © 2020 Barrett, Chen, Dai, Plaisance-Bonstaff, Del Valle and Qin.
Références
Virology. 2019 Oct;536:16-19
pubmed: 31394407
J Pediatr Hematol Oncol. 2008 Dec;30(12):920-4
pubmed: 19131781
Semin Immunol. 2013 Dec 15;25(6):389-93
pubmed: 24275600
Semin Immunol. 2013 Dec 15;25(6):394-407
pubmed: 24246227
Semin Immunol. 2013 Dec 15;25(6):469-84
pubmed: 24275598
Nat Rev Cancer. 2010 Oct;10(10):707-19
pubmed: 20865011
Science. 2006 Feb 10;311(5762):856-61
pubmed: 16469929
Viruses. 2014 Dec 11;6(12):4961-98
pubmed: 25514370
Cancer Treat Res. 2019;177:1-21
pubmed: 30523619
Nature. 2001 Jul 5;412(6842):99
pubmed: 11808612
J Virol. 2012 Nov;86(21):11663-74
pubmed: 22896623
Cytokine Growth Factor Rev. 1998 Mar;9(1):63-83
pubmed: 9720757
Trends Microbiol. 2017 Aug;25(8):648-661
pubmed: 28259385
J Virol. 2015 Jan;89(1):415-27
pubmed: 25320320
J Immunol. 1997 Feb 15;158(4):1887-94
pubmed: 9029130
Immunol Rev. 1992 Jun;127:147-55
pubmed: 1506004
Mol Cancer Ther. 2010 Jun;9(6):1485-8
pubmed: 20501803
Front Immunol. 2020 Feb 07;10:3084
pubmed: 32117196
Sci Signal. 2017 Aug 15;10(492):
pubmed: 28811383
Adv Virol. 2011;2011:
pubmed: 21625290
mBio. 2017 Oct 10;8(5):
pubmed: 29018115
Front Immunol. 2019 Sep 13;10:2025
pubmed: 31572353
J Virol. 2011 Dec;85(24):13290-7
pubmed: 21957289
Blood. 2013 Dec 19;122(26):4189-98
pubmed: 24174627
N Engl J Med. 2017 Sep 21;377(12):1119-1131
pubmed: 28845751
Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):282-7
pubmed: 17185418
J Virol. 2020 May 4;94(10):
pubmed: 32161170
J Virol. 2015 Oct 14;90(1):180-8
pubmed: 26468534
J Infect Dis. 2020 Jun 19;:
pubmed: 32561934
J Virol. 2013 Apr;87(8):4417-31
pubmed: 23388709
Science. 2011 Jan 21;331(6015):330-4
pubmed: 21252346
Proc Natl Acad Sci U S A. 2014 Nov 4;111(44):E4762-8
pubmed: 25341731
EMBO Rep. 2008 Oct;9(10):1006-12
pubmed: 18688256
Mol Ther. 2007 Jul;15(7):1264-72
pubmed: 17505479
J Virol. 2002 May;76(10):4688-98
pubmed: 11967286
Meta Gene. 2014 Jan 17;2:123-33
pubmed: 25606396
Nat Rev Rheumatol. 2019 Oct;15(10):612-632
pubmed: 31515542